Who we are
A preclinical provider in otology, we are uniquely qualified in the functions of the ear, a complex sensory organ which remains under-explored. Established in Boston, Paris, and Montpellier, we have state-of-the art laboratories, research experts in otology and neurosciences, as well as a global network of partners. This enables us to offer fully customizable and comprehensive R&D programs including pharmacokinetics, preclinical efficacy, and GLP ototoxicology studies.
Our talented team is deeply committed to its mission: “To accelerate the development of novel therapies to prevent and treat hearing loss, tinnitus, and otitis, in order to provide solutions to millions of patients suffering from ear diseases, waiting for effective treatment.”
Drawing on our extensive industrial background, we also provide consultancy services to speed up your product’s R&D cycle time. CILcare works with academic research centers, private companies operating in pharmaceuticals, medical devices, nutraceuticals, and animal health, as well as patient associations and venture capital funds. A trusted CRO partner with the ambition to catalyze research & development in hearing disorders on a global scale, join us as we fight for this cause:
The care of this extraordinary sense: hearing.
CILcare has entered into several research collaborations with academics and industries, leveraging its expertise in ear diseases to accelerate the discovery of breakthrough therapeutics.
Access to library of assets qualified to target hearing disorders:
- Draper (US-based R&D Institute): development of an innovative intracochlear drug delivery device
This collaboration allows us to test Draper’s novel intracochlear drug delivery (ICDD) device for hearing loss and related indications. The preclinical trials will be conducted with CILcare’s models, with operational support from CBSET’s GLP-compliant laboratories. Biotech and pharma companies involved in ear disorders are invited to join the consortium to assess the effect of their drug candidates using the novel device.
- PAM Alliance (Russia): assessment of unseen innovative molecules in the hearing field
CILcare has entered a partnership with Park of Active Molecules, a Russian biopharmaceutical alliance of competencies, developing original active compounds for the pharmaceutical industry. The goal of this partnership is to test the efficacy and safety of their new molecules for hearing impairments.
Development of new models and methods for innovative solutions to hearing loss indication:
- Z-Ear: development of a zebrafish screening model for hair cell regeneration, with the Institute for Regenerative Medicine and Biotherapy (IRMB) of Montpellier, and Azelead
- CochleOfix: optimization of an automated hair cell count with KeenEye and the Institute of vision
- Detec-T, DETECT2: determination of markers to detect tinnitus in rodents, with the research Unit of Montpellier University and CNRS
- SAMOB: development of senescence-accelerated mouse model to address the relationship between auditory impairment, neuroprotection, memory, and diabetes, with Amylgen and Physiogenex
Highly committed to continuous research, CILcare is working on innovative research projects with academics for optimizing characterization and measurements of candidate efficacy on hearing deficiencies.